Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerSuzanne L. Topalian, Mario Sznol, F. Stephen Hodi et al.|New England Journal of Medicine|2012Cited by 12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerJulie R. Brahmer, Jon M. Wigginton, Scott S. Tykodi et al.|New England Journal of Medicine|2012Cited by 8k
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F. McDermott, Michael B. Atkins, Charles G. Drake et al.|Journal of Clinical Oncology|2015Cited by 443
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Christopher J. Sweeney, Kobe Yuen et al.|Nature Medicine|2022Cited by 241
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim resultsChristine D. Palmer, Karin Jooss, Amy Rappaport et al.|Nature Medicine|2022Cited by 225